Geron Corporation Skyrockets as Cancer Drug is Highly Effective in Trial, Shares Up +44.72% @ Market Close (November 7, 2013)
Geron Corp said 22 percent of patients treated by its experimental blood cancer drug in a clinical trial were free of the disease, and its shares more than doubled in value in early trading. The company also said that one patient, of the first 18 patients enrolled in the trial, showed a partial remission to the drug, known as imetelstat.
Help employers find you! Check out all the jobs and post your resume.